180 Life Sciences Corp.

Equities

KBLM

US68236V3024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 17/05/2024 am IST			5-day change	1st Jan Change
1.65 ^USD	-14.95%		-17.09%	-59.32%

09/05	180 Life Sciences Corp. Announces Management Changes	CI
09/05	180 Life Sciences Corp. Announces Chief Executive Officer Changes	CI

180 Life Sciences Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 16, 2023 at 01:46 am IST

180 Life Sciences Corp. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 4.76 million compared to net income of USD 1.56 million a year ago.

Basic loss per share from continuing operations was USD 24.13 compared to basic earnings per share from continuing operations of USD 17.48 a year ago. Diluted loss per share from continuing operations was USD 24.13 compared to diluted earnings per share from continuing operations of USD 17.48 a year ago.

Latest news about 180 Life Sciences Corp.

180 Life Sciences Corp. Announces Management Changes	09/05	CI
180 Life Sciences Corp. Announces Chief Executive Officer Changes	09/05	CI
180 Life Sciences Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03	CI
180 Life Sciences Corp. Announces Board Changes	11/03	CI
180 Life Sciences Corp. Appoints Blair Jordan as A Member of the Board of Directors	29/02	CI
180 Life Sciences to Conduct 1-For-19 Reverse Stock Split	26/02	MT
180 Life Sciences Corp. announced a financing transaction	21/02	CI
180 Life Sciences Corp. Announces Board Resignations	22/12	CI
180 Life Sciences Corp. Announces Resignation of Donald A. Mcgovern, as Member of the Board of Directors	20/12	CI
180 Life Sciences Hires Financial Adviser to Help Explore Strategic Alternatives	04/12	CI
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives	04/12	CI
180 Life Sciences Announces Review of Strategic Alternatives	29/11	CI
Certain Warrants of 180 Life Sciences Corp. are subject to a Lock-Up Agreement Ending on 13-NOV-2023.	13/11	CI
Certain Stock Options of 180 Life Sciences Corp. are subject to a Lock-Up Agreement Ending on 13-NOV-2023.	13/11	CI
Certain Common Stock of 180 Life Sciences Corp. are subject to a Lock-Up Agreement Ending on 13-NOV-2023.	13/11	CI
180 Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
180 Life Sciences Corp. Receives Formal Written Scientific Response from the United Kingdom's Medicines and Healthcare Products Regulatory Agency	19/23/19	CI
180 Life Sciences Corp. and Oxford University Innovation Limited Enter into a Termination Letter, Formally Terminate the License	29/23/29	CI
180 Life Sciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	16/23/16	CI
Top Premarket Gainers	09/23/09	MT
180 Life Sciences Announces an Agreement for A Clinical Pharmacology Study Testing A New Formulation of Cbd for Enhanced Oral Uptake	07/23/07	CI
180 Life Sciences Corp. Provides Update on Regulatory Approval Process in the UK and US for Dupuytren's Disease Treatment	03/23/03	CI
180 Life Sciences Corp. Announces the Filing of A Provisional Patent Describing the Combination of CBD with GLP-1 Agonists to Suppress Appetite	31/23/31	CI
180 Life Sciences Corp.(NasdaqCM:ATNF) dropped from Russell 3000E Growth Index	23/23/23	CI
180 Life Sciences Corp.(NasdaqCM:ATNF) dropped from Russell 3000E Value Index	23/23/23	CI

Chart 180 Life Sciences Corp.

Duration

Period

More charts

Company Profile

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor (anti-TNF). SCAs platform is focused on drugs which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). a7nAChR platform is focused on alpha 7 nicotinic acetylcholine receptor (a7nAChR). It is conducting clinical trials only for certain indications under the anti-TNF platform. The Company is undertaking preclinical research and development activities for the SCA platform.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
180 LIFE SCIENCES CORP.	-59.32%	1.65M
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	113B
REGENERON PHARMACEUTICALS, INC.	+10.21%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.90%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.17%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.52B

Bio Therapeutic Drugs